234 related articles for article (PubMed ID: 31076742)
1. Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic Predisposition.
Vos JR; Fakkert IE; de Hullu JA; van Altena AM; Sie AS; Ouchene H; Willems RW; Nagtegaal ID; Jongmans MCJ; Mensenkamp AR; Woldringh GH; Bulten J; Leter EM; Kets CM; Simons M; Ligtenberg MJL; Hoogerbrugge N;
J Natl Cancer Inst; 2020 Feb; 112(2):161-169. PubMed ID: 31076742
[TBL] [Abstract][Full Text] [Related]
2. Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients.
Capoluongo E; Ellison G; López-Guerrero JA; Penault-Llorca F; Ligtenberg MJL; Banerjee S; Singer C; Friedman E; Markiefka B; Schirmacher P; Büttner R; van Asperen CJ; Ray-Coquard I; Endris V; Kamel-Reid S; Percival N; Bryce J; Röthlisberger B; Soong R; de Castro DG
Semin Oncol; 2017 Jun; 44(3):187-197. PubMed ID: 29248130
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of BRCA1 and BRCA2 pathogenic sequence variants in ovarian cancer patients in the Gulf region: the PREDICT study.
Azribi F; Abdou E; Dawoud E; Ashour M; Kamal A; Al Sayed M; Burney I
BMC Cancer; 2021 Dec; 21(1):1350. PubMed ID: 34930165
[TBL] [Abstract][Full Text] [Related]
4. Genetic and epigenetic profiling of BRCA1/2 in ovarian tumors reveals additive diagnostic yield and evidence of a genomic BRCA1/2 DNA methylation signature.
Aref-Eshghi E; McGee JD; Pedro VP; Kerkhof J; Stuart A; Ainsworth PJ; Lin H; Volodarsky M; McLachlin CM; Sadikovic B
J Hum Genet; 2020 Oct; 65(10):865-873. PubMed ID: 32483276
[TBL] [Abstract][Full Text] [Related]
5. Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas.
Weren RD; Mensenkamp AR; Simons M; Eijkelenboom A; Sie AS; Ouchene H; van Asseldonk M; Gomez-Garcia EB; Blok MJ; de Hullu JA; Nelen MR; Hoischen A; Bulten J; Tops BB; Hoogerbrugge N; Ligtenberg MJ
Hum Mutat; 2017 Feb; 38(2):226-235. PubMed ID: 27767231
[TBL] [Abstract][Full Text] [Related]
6. Impact of proactive high-throughput functional assay data on BRCA1 variant interpretation in 3684 patients with breast or ovarian cancer.
Kim HK; Lee EJ; Lee YJ; Kim J; Kim Y; Kim K; Lee SW; Chang S; Lee YJ; Lee JW; Lee W; Chun S; Son BH; Jung KH; Kim YM; Min WK; Ahn SH
J Hum Genet; 2020 Mar; 65(3):209-220. PubMed ID: 31907386
[TBL] [Abstract][Full Text] [Related]
7. Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883).
Hauke J; Hahnen E; Schneider S; Reuss A; Richters L; Kommoss S; Heimbach A; Marmé F; Schmidt S; Prieske K; Gevensleben H; Burges A; Borde J; De Gregorio N; Nürnberg P; El-Balat A; Thiele H; Hilpert F; Altmüller J; Meier W; Dietrich D; Kimmig R; Schoemig-Markiefka B; Kast K; Braicu E; Baumann K; Jackisch C; Park-Simon TW; Ernst C; Hanker L; Pfisterer J; Schnelzer A; du Bois A; Schmutzler RK; Harter P
J Med Genet; 2019 Sep; 56(9):574-580. PubMed ID: 30979843
[TBL] [Abstract][Full Text] [Related]
8. The most efficient and effective BRCA1/2 testing strategy in epithelial ovarian cancer: Tumor-First or Germline-First?
Witjes VM; Ligtenberg MJL; Vos JR; Braspenning JCC; Ausems MGEM; Mourits MJE; de Hullu JA; Adang EMM; Hoogerbrugge N
Gynecol Oncol; 2023 Jul; 174():121-128. PubMed ID: 37182432
[TBL] [Abstract][Full Text] [Related]
9. BRCA1/2 testing: therapeutic implications for breast cancer management.
Tung NM; Garber JE
Br J Cancer; 2018 Jul; 119(2):141-152. PubMed ID: 29867226
[TBL] [Abstract][Full Text] [Related]
10. Frontline PARP inhibitor maintenance therapy in ovarian cancer: A Society of Gynecologic Oncology practice statement.
Pothuri B; O'Cearbhaill R; Eskander R; Armstrong D
Gynecol Oncol; 2020 Oct; 159(1):8-12. PubMed ID: 32778410
[TBL] [Abstract][Full Text] [Related]
11.
Talwar V; Rauthan A
Indian J Cancer; 2022 Mar; 59(Supplement):S56-S67. PubMed ID: 35343191
[TBL] [Abstract][Full Text] [Related]
12. Targeted molecular profiling of epithelial ovarian cancer from Italian BRCA wild-type patients with a BRCA and PARP pathways gene panel.
Salvati A; Carnevali I; Alexandrova E; Facchi S; Ronchi S; Libera L; Sahnane N; Memoli D; Lamberti J; Amabile S; Pepe S; Tarallo R; Sessa F; Weisz A; Tibiletti MG; Rizzo F
Exp Mol Pathol; 2022 Oct; 128():104833. PubMed ID: 36165864
[TBL] [Abstract][Full Text] [Related]
13. Genetic testing in ovarian cancer - clinical impact and current practices.
Knabben L; Imboden S; Mueller MD
Horm Mol Biol Clin Investig; 2019 Oct; 41(3):. PubMed ID: 31577534
[TBL] [Abstract][Full Text] [Related]
14. Next-generation sequencing-based BRCA testing on cytological specimens from ovarian cancer ascites reveals high concordance with tumour tissue analysis.
Fumagalli C; Rappa A; Casadio C; Betella I; Colombo N; Barberis M; Guerini-Rocco E
J Clin Pathol; 2020 Mar; 73(3):168-171. PubMed ID: 31537627
[TBL] [Abstract][Full Text] [Related]
15. Somatic mRNA Analysis of BRCA1 Splice Variants Provides a Direct Theranostic Impact on PARP Inhibitors.
Chevalier LM; Billaud A; Fronteau S; Dauvé J; Patsouris A; Verriele V; Morel A
Mol Diagn Ther; 2020 Apr; 24(2):233-243. PubMed ID: 32124385
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients.
Rodriguez-Freixinos V; Fariñas-Madrid L; Gil-Martin M; Barretina-Ginesta P; Romeo M; Villacampa G; Pardo B; Ahmed H; Recalde S; Piulats JM; Gómez-Plaza MC; Gil-Moreno A; Sala E; Martínez-Román S; Ponce J; Meléndez C; Carballas E; Dienstmann R; Oaknin A
Gynecol Oncol; 2019 Feb; 152(2):270-277. PubMed ID: 30551885
[TBL] [Abstract][Full Text] [Related]
17. Examining the Diagnostic Yield of Tumour Testing and Qualifying Germline Concordance for Hereditary Cancer Variants in Patients with High-Grade Serous Carcinoma.
Goebel EA; Kerkhof J; Dzyubak O; McLachlin CM; McGee J; Sadikovic B
Genes (Basel); 2022 Aug; 13(8):. PubMed ID: 36011309
[TBL] [Abstract][Full Text] [Related]
18. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
[TBL] [Abstract][Full Text] [Related]
19. Validation and Implementation of BRCA1/2 Variant Screening in Ovarian Tumor Tissue.
de Jonge MM; Ruano D; van Eijk R; van der Stoep N; Nielsen M; Wijnen JT; Ter Haar NT; Baalbergen A; Bos MEMM; Kagie MJ; Vreeswijk MPG; Gaarenstroom KN; Kroep JR; Smit VTHBM; Bosse T; van Wezel T; van Asperen CJ
J Mol Diagn; 2018 Sep; 20(5):600-611. PubMed ID: 29936257
[TBL] [Abstract][Full Text] [Related]
20. Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy.
Walsh CS
Gynecol Oncol; 2015 May; 137(2):343-50. PubMed ID: 25725131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
